Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S492000
Reexamination Certificate
active
07115648
ABSTRACT:
Heterocyclic amides of formula (1)wherein:R1is independently selected from, for example, C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylC1-3alkyl, C1-6alkoxy, C5-7cycloalkoxy, C5-7cycloalkylC1-3alkoxy, heterocyclyl, heterocyclylC1-3alkyl, heterocyclyloxy or heterocyclylC1-3alkoxy,R2is phenyl or heteroaryl;R3is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkyl, C1-4alkoxy, C1-4alkanoyl, fluoromethyl, difluoromethyl trifluoromethyl and trifluoromethoxy;or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
REFERENCES:
patent: 3706810 (1972-12-01), Brabander et al.
patent: 4599198 (1986-07-01), Hoover
patent: 4668769 (1987-05-01), Hoover
patent: 4720503 (1988-01-01), Witzel
patent: 4751231 (1988-06-01), Halczenko
patent: 4786641 (1988-11-01), Goldmann
patent: 4794120 (1988-12-01), Manoury
patent: 5863903 (1999-01-01), Lundgren
patent: 5998463 (1999-12-01), Hulin
patent: 2004/0002495 (2004-01-01), Sher
patent: 2004/0142938 (2004-07-01), Sher et al.
patent: 2004/0220229 (2004-11-01), Bussolotti et al.
patent: 2004/0266768 (2004-12-01), Schoenafinger et al.
patent: 200740 (1983-06-01), None
patent: 4445968 (1996-06-01), None
patent: 697403 (1996-02-01), None
patent: 697403 (1996-02-01), None
patent: 0846464 (1998-06-01), None
patent: 0884050 (1998-12-01), None
patent: 0978279 (2000-02-01), None
patent: 1149580 (2001-02-01), None
patent: 1177791 (2001-07-01), None
patent: 1125580 (2001-08-01), None
patent: 1134213 (2001-09-01), None
patent: 1136071 (2001-09-01), None
patent: 1 338 594 (2003-08-01), None
patent: 1 340 500 (2003-09-01), None
patent: 1088824 (2004-01-01), None
patent: 1145717 (2004-05-01), None
patent: 2081747 (1996-03-01), None
patent: 021247565 (1990-05-01), None
patent: 04179949 (1992-06-01), None
patent: 2001 089368 (2001-04-01), None
patent: 2001 206856 (2001-07-01), None
patent: 2001247565 (2001-09-01), None
patent: 2004196702 (2004-07-01), None
patent: WO-93/25574 (1993-12-01), None
patent: WO-95/24391 (1995-09-01), None
patent: WO-96/39384 (1996-12-01), None
patent: WO-96/39385 (1996-12-01), None
patent: WO-97/09040 (1997-03-01), None
patent: WO-97/31901 (1997-09-01), None
patent: WO-97/45425 (1997-12-01), None
patent: WO-98/27108 (1998-06-01), None
patent: WO-98/40353 (1998-09-01), None
patent: WO-98/50359 (1998-11-01), None
patent: WO-99/26659 (1999-06-01), None
patent: WO-99/36393 (1999-07-01), None
patent: WO-00/42213 (2000-07-01), None
patent: WO-00/47206 (2000-08-01), None
patent: WO-01/05954 (2001-01-01), None
patent: WO-01/23347 (2001-04-01), None
patent: 01/32622 (2001-05-01), None
patent: WO-01/32654 (2001-05-01), None
patent: WO-01/52825 (2001-07-01), None
patent: WO-01/68055 (2001-09-01), None
patent: WO-01/68092 (2001-09-01), None
patent: WO-01/68603 (2001-09-01), None
patent: WO-01/94300 (2001-12-01), None
patent: WO-01/96311 (2001-12-01), None
patent: WO-01/96347 (2001-12-01), None
patent: 02/20530 (2002-03-01), None
patent: WO-02/26714 (2002-04-01), None
patent: WO-02/34718 (2002-05-01), None
patent: WO-02/080844 (2002-10-01), None
patent: WO-02/096864 (2002-12-01), None
patent: WO-02/098348 (2002-12-01), None
patent: WO-03/037864 (2003-05-01), None
patent: 03/045920 (2003-06-01), None
patent: 03/072570 (2003-09-01), None
patent: 03/074484 (2003-09-01), None
patent: 03/074513 (2003-09-01), None
patent: 03/074517 (2003-09-01), None
patent: 03/074531 (2003-09-01), None
patent: 03/074532 (2003-09-01), None
patent: 03/091213 (2003-11-01), None
patent: 2004/031193 (2004-04-01), None
patent: 2004/031194 (2004-04-01), None
patent: 2004/041780 (2004-05-01), None
patent: 2004/092158 (2004-10-01), None
patent: 2004/104001 (2004-12-01), None
patent: 2004113345 (2004-12-01), None
patent: 2005/01981 (2005-02-01), None
patent: 2005/013975 (2005-02-01), None
patent: 2005/018637 (2005-03-01), None
patent: 2005/019172 (2005-03-01), None
patent: 2005/020985 (2005-03-01), None
patent: 2005/020986 (2005-03-01), None
patent: 2005/020987 (2005-03-01), None
Crochet, R.A., et al., “Synthesis of Substituted Thieno[2,3-b] pyrroles,” vol. 11, 143-150 (Apr. 1974).
Hartman, G.D., et al., “The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides,” Heterocycles, 29(10):1943-1949 (1989).
Hoover, D.J., et al., “Indole-2-carboxamide inhibitors of Human Liver Glycogen Phosphorylase,” J. Med. Chem., 41:2934-2938 (1998).
Hudson, S., et al., “The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats,” J. Physiol., 539:52-53 (2002).
Jakobsen, P., et al., “Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase.,” Zoo Bioorganic Med. Chem., 9:733-744 (2001).
Martin, W.H., et al., “Discovery of a human liver glycogen phosphorylase inhbitor that lowers blood glucose in vivo,” PNAS, 95:1776-1781 (Feb. 1998).
McCormack, J.G., et al., “Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy,” Curr. Pharmaceutical Design, 7:1451-1474 (2001).
Oikonomakos, N.G., et al., “Allosteric inhibition of glycogen phosphorylase alpha by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate,” Protein Sci., 8:1930-1945 (1999).
Rath, V.L. et al., “Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core,” Mol. Cell, 6:139-148 (Jul. 2000).
Rosauer, K.G., et al., “Novel, 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a,” Bioorganic & Medicinal Chemistry Letters, 13:4385-4388 (2003).
Soman, G., et al. “Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase beta,” Biochimica et Biophysica Acta, 358:359-362 (1974).
Soman, G., et al., “The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase beta,” Biochem. J., 147:369-371 (1975).
Treadway, J.L., et al., “Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus,” Exp. Opin. Invest. Drugs, 10(3):439-454 (2001).
Venkatarangan, P., et al., “Prediction of Ligand-REceptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase,” J. Med. Chem., 42:2169-2179 (1999).
Vertigan, H., “Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents,” Diabetes, 47, Supp., 589, A214.
Barlett, J. et al. “In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase”, ADA San Diego (2005).
Green, A R. et al. “The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation”, J. Biol Chem, 279(45), 46474-46482 (2004).
Roberts, P A. et al. “The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle”, J Physiology-London 545(1), 297-304 (2002).
Simpson, I. et al. “Novel Orally Active Amino-indan Inhibitors: In Vitro SAR and Crystallographic Studies, ” Poster, Cambridge Med Chem Conference (Sep. 2005. Poster EOM.
Birch, A., et al., “Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies, ” Poster, Cambridge Med Chem Symposium (Sep. 2003).
Freeman, S., et al., “Effect of Glucose on Rat and Human Liver Glycogen Phosphorylasea Activity and Potency
AstraZeneca AB
Nolan Jason M.
Saeed Kamal A.
LandOfFree
Indole-amide derivatives and their use as glycogen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole-amide derivatives and their use as glycogen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole-amide derivatives and their use as glycogen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716617